Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
Part of paid clinical trials in Baltimore, Maryland.
- Sponsor
- University of Maryland, Baltimore
- Study ID
- NCT04401982
- Status
- Completed
Conditions
- Ocular Hypertension
- Suspect Glaucoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 88 Years
- Healthy Volunteers
- Not accepted
Interventions
- Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks — DRUGNetarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks will be administered
Study Details
Rhopressa effectively lowers intra-ocular pressure by improving conventional outflow and decreasing episcleral venous pressure. While this may result in improved episcleral venous flow, current methods to quantify episcleral blood flow in vivo are rudimentary and unable to accurately and precisely determine flow. Proof that Rhopressa effectively increases episcleral venous flow would differentiate it from other medications. Furthermore, this evidence could galvanize interest in the use of Rhopressa after popular Minimally Invasive Glaucoma Surgery (MIGS) procedures. In future studies, MIGS procedures could be used to improve the proximal outflow pathway, and Rhopressa to enhance distal outflow. Specific Aim: To determine the effect of Rhopressa on episcleral venous outflow and retinal blood flow in a cohort of treatment-naïve ocular hypertensive and glaucoma suspect patients. Hypothesis: Rhopressa increases episcleral venous flow and retinal blood flow from baseline at both 1 hour and 1 week after initiation of therapy.
Key Dates
- Start date
- Mar 15, 2021
- Status verified
- Mar 2022
- Primary completion
- Feb 22, 2022
- Completion
- Feb 22, 2022
Study Design
- Enrollment
- 10 participants (actual)
Arms
- Arm: Glaucoma SuspectIndividuals with a diagnosis of glaucoma suspect
Primary Outcome Measure
Change in episcleral venous blood flow with Rhopressa [ Time Frame: 1 year ]
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | - |
| University Physicians Inc. | Baltimore | Maryland | 21201 | - |
| UM Faculty Physicians, Inc. | 5900 Waterloo Crossing | Columbia | Maryland | 21045 | - |
| Maryland Eye Consultants and Surgeons | Silver Spring | Maryland | 20902 | - |
Find similar trials in Baltimore, MD
Related Studies
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.PHASE3 · Recruiting · Amneal Pharmaceuticals, LLC · Newport Beach, California
- Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority TrialRecruiting · 59th Medical Wing · Lackland Air Force Base, Texas
- A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both EyesPHASE1 · Recruiting · Amneal Pharmaceuticals, LLC · Bakersfield, California
- Implementing AI-based Glaucoma Screening Within Federally Qualified Health CentersRecruiting · University of Alabama at Birmingham · Birmingham, Alabama